Diabetes drug could help kidney dialysis patients

NCT ID NCT06913647

Recruiting now Disease control Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether canagliflozin, a diabetes drug, can improve fluid removal and reduce scarring in people on peritoneal dialysis for kidney failure. Thirty adults will receive either the drug or a placebo for 26 weeks, then switch. The goal is to see if the drug helps the dialysis membrane work better and stay healthier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Canagliflozin (Invokana) 300 mg tablet
What this could lead to: If it works, this could point toward a way to make peritoneal dialysis more effective and slow damage to the lining of the belly.
What could go wrong: This is a small, early-phase proof-of-concept trial with only 30 participants. The drug may not improve dialysis outcomes or could cause side effects like ketoacidosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD (CHRONIC KIDNEY DISEASE) STAGE 5D are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure kidney failure Peritoneal Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD (CHRONIC KIDNEY DISEASE) STAGE 5D ESRD

Contacts and locations

Locations

Research Institute-McGill University Health Center
RECRUITING

Montreal, Quebec, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.